CD4 and myeloid sarcoma: Besides MR studies, in vitro studies in T-cells from MS patients showed that blockade of IL-6 signaling by anti-IL-6R monoclonal antibody reduces IL-17 production and elevates IL-10 release by activated CD4+ T cells (52).